The Gut Microbial-Derived Metabolite Trimethylamine N-Oxide and Atrial Fibrillation: Relationships, Mechanisms, and Therapeutic Strategies

References

• Xu F, Fu Y, Sun TY, et al. The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases. Microbiome. 2020;8(1):145. doi:10.1186/s40168-020-00923-933032658
   PubMed Web of Science ®Google Scholar
• Peng J, Xiao X, Hu M, Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018;214:153–157. doi:10.1016/j.lfs.2018.10.06330385177
   PubMed Web of Science ®Google Scholar
• Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183–1196. doi:10.1161/CIRCRESAHA.117.30971528360349
   PubMed Web of Science ®Google Scholar
• Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553–570. doi:10.1161/CIRCRESAHA.120.31624232762536
   PubMed Web of Science ®Google Scholar
• Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360. doi:10.3389/fphar.2019.0136031803054
   PubMed Web of Science ®Google Scholar
• Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124. doi:10.1016/j.cell.2016.02.01126972052
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. doi:10.1161/CIRCRESAHA.116.30536025599331
   PubMed Web of Science ®Google Scholar
• Li XS, Obeid S, Wang Z, et al. Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. Eur Heart J. 2019;40(32):2700–2709. doi:10.1093/eurheartj/ehz25931049589
   PubMed Web of Science ®Google Scholar
• Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: a review. Nutrients. 2020;12(10):2982. doi:10.3390/nu12102982
   PubMed Web of Science ®Google Scholar
• Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-Oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–313. doi:10.1681/ASN.201411106326229137
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Transl Res. 2021;228:109–125. doi:10.1016/j.trsl.2020.08.00732841736
   PubMed Web of Science ®Google Scholar
• Schiattarella GG, Sannino A, Toscano E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38(39):2948–2956. doi:10.1093/eurheartj/ehx34229020409
   PubMed Web of Science ®Google Scholar
• Zhang P, Zou JZ, Chen J, et al. Association of trimethylamine N-oxide with cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail. 2020;42(1):1004–1014. doi:10.1080/0886022X.2020.182286832985309
   PubMed Web of Science ®Google Scholar
• Meng G, Zhou X, Wang M, et al. Gut microbe-derived metabolite trimethylamine N-oxide activates the cardiac autonomic nervous system and facilitates ischemia-induced ventricular arrhythmia via two different pathways. EBioMedicine. 2019;44:656–664. doi:10.1016/j.ebiom.2019.03.06630954457
   PubMed Web of Science ®Google Scholar
• Svingen GFT, Zuo H, Ueland PM, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int J Cardiol. 2018;267:100–106. doi:10.1016/j.ijcard.2018.04.12829957250
   PubMed Web of Science ®Google Scholar
• Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787–8803. doi:10.3748/wjg.v21.i29.878726269668
   PubMed Web of Science ®Google Scholar
• Zhou X, Jin M, Liu L, Yu Z, Lu X, Zhang H. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Fail. 2020;7(1):188–193. doi:10.1002/ehf2.1255231960610
   PubMed Web of Science ®Google Scholar
• Zuo K, Liu X, Wang P, et al. Metagenomic data-mining reveals enrichment of trimethylamine-N-oxide synthesis in gut microbiome in atrial fibrillation patients. BMC Genomics. 2020;21(1):526. doi:10.1186/s12864-020-06944-w32731896
   PubMed Web of Science ®Google Scholar
• Ottiger M, Nickler M, Steuer C, et al. Gut, microbiota-dependent trimethylamine-N-oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease. Nutrition (Burbank, Los Angeles County, Calif). 2018;45:135–41.e1. doi:10.1016/j.nut.2017.07.001
   Web of Science ®Google Scholar
• Drapala A, Szudzik M, Chabowski D, et al. Heart failure disturbs gut-blood barrier and increases plasma trimethylamine, a toxic bacterial metabolite. Int J Mol Sci. 2020;21(17):6161. doi:10.3390/ijms21176161
   Web of Science ®Google Scholar
• Schugar RC, Shih DM, Warrier M, et al. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep. 2017;19(12):2451–2461. doi:10.1016/j.celrep.2017.05.07728636934
   PubMed Web of Science ®Google Scholar
• Chen S, Henderson A, Petriello MC, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab. 2019;30(6):1141–51.e5. doi:10.1016/j.cmet.2019.08.02131543404
   PubMed Web of Science ®Google Scholar
• Din AU, Hassan A, Zhu Y, Yin T, Gregersen H, Wang G. Amelioration of TMAO through probiotics and its potential role in atherosclerosis. Appl Microbiol Biotechnol. 2019;103(23–24):9217–9228. doi:10.1007/s00253-019-10142-431655880
   PubMed Web of Science ®Google Scholar
• van Ouwerkerk AF, Bosada FM, van Duijvenboden K, et al. Identification of atrial fibrillation associated genes and functional non-coding variants. Nat Commun. 2019;10(1):4755. doi:10.1038/s41467-019-12721-531628324
   PubMed Web of Science ®Google Scholar
• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. doi:10.1161/CIRCULATIONAHA.113.00511924345399
   PubMed Web of Science ®Google Scholar
• Kolek MJ, Graves AJ, Xu M, et al. Evaluation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records. JAMA Cardiol. 2016;1(9):1007–1013. doi:10.1001/jamacardio.2016.336627732699
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa61232860505
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang S, Li B, et al. Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res. 2021. doi:10.1093/cvr/cvab114
   Web of Science ®Google Scholar
• Nguyen BO, Meems LMG, van Faassen M, et al. Gut-microbe derived TMAO and its association with more progressed forms of AF: results from the AF-RISK study. Int J Cardiol Heart Vasc. 2021;34:100798. doi:10.1016/j.ijcha.2021.10079834095450
   PubMed Web of Science ®Google Scholar
• Jia J, Dou P, Gao M, et al. Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional Mendelian randomization analysis. Diabetes. 2019;68(9):1747–1755. doi:10.2337/db19-015331167879
   PubMed Web of Science ®Google Scholar
• Li J, Zuo K, Zhang J, et al. Shifts in gut microbiome and metabolome are associated with risk of recurrent atrial fibrillation. J Cell Mol Med. 2020;24(22):13356–13369. doi:10.1111/jcmm.1595933058365
   PubMed Web of Science ®Google Scholar
• Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–243. doi:10.1038/nrcardio.2015.225622848
   PubMed Web of Science ®Google Scholar
• Boos CJ. Infection and atrial fibrillation: inflammation begets AF. Eur Heart J. 2020;41(10):1120–1122. doi:10.1093/eurheartj/ehz95331971996
   PubMed Web of Science ®Google Scholar
• Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–2270. doi:10.1016/j.jacc.2012.04.06323194937
   PubMed Web of Science ®Google Scholar
• Yu L, Meng G, Huang B, et al. A potential relationship between gut microbes and atrial fibrillation: trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int J Cardiol. 2018;255:92–98. doi:10.1016/j.ijcard.2017.11.07129425570
   PubMed Web of Science ®Google Scholar
• Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. doi:10.3390/nu10101398
   PubMed Web of Science ®Google Scholar
• Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-Oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc. 2017;6(9). doi:10.1161/JAHA.117.006347
   Web of Science ®Google Scholar
• Li X, Geng J, Zhao J, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 Inflammasome. Front Physiol. 2019;10:866. doi:10.3389/fphys.2019.0086631354519
   PubMed Web of Science ®Google Scholar
• Ke Y, Li D, Zhao M, et al. Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress. Free Radic Biol Med. 2018;116:88–100. doi:10.1016/j.freeradbiomed.2018.01.00729325896
   PubMed Web of Science ®Google Scholar
• Büttner P, Okun JG, Hauke J, et al. Trimethylamine N-oxide in atrial fibrillation progression. Int J Cardiol Heart Vasc. 2020;29:100554. doi:10.1016/j.ijcha.2020.10055432885030
   PubMed Web of Science ®Google Scholar
• Papandreou C, Bulló M, Hernández-Alonso P, et al. Choline metabolism and risk of atrial fibrillation and heart failure in the PREDIMED study. Clin Chem. 2021;67(1):288–297. doi:10.1093/clinchem/hvaa22433257943
   PubMed Web of Science ®Google Scholar
• Gawałko M, Jespersen T, Dobrev D, Linz D. The gut microbial-derived metabolite trimethylamine N-oxide: a missing link between lifestyle-components and atrial fibrillation? Int J Cardiol Heart Vasc. 2020;29:100581. doi:10.1016/j.ijcha.2020.10058132885798
   PubMed Web of Science ®Google Scholar
• van den Munckhof ICL, Kurilshikov A, Ter Horst R, et al. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obes Rev. 2018;19(12):1719–1734. doi:10.1111/obr.1275030144260
   PubMed Web of Science ®Google Scholar
• Ge X, Zheng L, Zhuang R, et al. The gut microbial metabolite trimethylamine N-oxide and hypertension risk: a systematic review and dose-response meta-analysis. Adv Nutr. 2020;11(1):66–76. doi:10.1093/advances/nmz06431269204
   PubMed Web of Science ®Google Scholar
• Gawałko M, Linz D, Dobrev D. Gut-microbiota derived TMAO: a risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation? Int J Cardiol Heart Vasc. 2021;34:100818. doi:10.1016/j.ijcha.2021.10081834189250
   PubMed Web of Science ®Google Scholar
• Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325. doi:10.1152/physrev.00031.200921248168
   PubMed Web of Science ®Google Scholar
• Yin J, Liao SX, He Y, et al. Dysbiosis of gut microbiota with reduced Trimethylamine-N-Oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J Am Heart Assoc. 2015;4(11). doi:10.1161/JAHA.115.002699
   Web of Science ®Google Scholar
• Wu C, Xue F, Lian Y, et al. Relationship between elevated plasma trimethylamine N-oxide levels and increased stroke injury. Neurology. 2020;94(7):e667–e77. doi:10.1212/WNL.000000000000886231907287
   PubMed Web of Science ®Google Scholar
• Schneider C, Okun JG, Schwarz KV, et al. Trimethylamine-N-oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days. Eur J Neurol. 2020;27(8):1596–1603. doi:10.1111/ene.1425332282978
   PubMed Web of Science ®Google Scholar
• Rexidamu M, Li H, Jin H, Huang J. Serum levels of Trimethylamine-N-oxide in patients with ischemic stroke. Biosci Rep. 2019;39(6). doi:10.1042/BSR20190515
   Web of Science ®Google Scholar
• Gong D, Zhang L, Zhang Y, Wang F, Zhao Z, Zhou X. Gut microbial metabolite trimethylamine N-oxide is related to thrombus formation in atrial fibrillation patients. Am J Med Sci. 2019;358(6):422–428. doi:10.1016/j.amjms.2019.09.00231666184
   PubMed Web of Science ®Google Scholar
• Liang Z, Dong Z, Guo M, et al. Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation. J Biochem Mol Toxicol. 2019;33(2):e22246. doi:10.1002/jbt.2224630370581
   PubMed Web of Science ®Google Scholar
• Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314(10):1030–1038. doi:10.1001/jama.2015.1072526318604
   PubMed Web of Science ®Google Scholar
• Chelu MG, Li N. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: are we there yet? Int J Cardiol. 2018;267:116–117. doi:10.1016/j.ijcard.2018.05.10629885821
   PubMed Web of Science ®Google Scholar
• Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. J Am Coll Cardiol. 2007;50(1):61–68. doi:10.1016/j.jacc.2007.02.06617601547
   PubMed Web of Science ®Google Scholar
• Wang G, Kong B, Shuai W, Fu H, Jiang X, Huang H. 3,3-Dimethyl-1-butanol attenuates cardiac remodeling in pressure-overload-induced heart failure mice. J Nutr Biochem. 2020;78:108341. doi:10.1016/j.jnutbio.2020.10834132004931
   PubMed Web of Science ®Google Scholar
• Li Z, Wu Z, Yan J, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis. Lab Invest. 2019;99(3):346–357. doi:10.1038/s41374-018-0091-y30068915
   PubMed Web of Science ®Google Scholar
• Brunt VE, Gioscia-Ryan RA, Casso AG, et al. Trimethylamine-N-Oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension (Dallas, Tex: 1979). 2020;76(1):101–112. doi:10.1161/HYPERTENSIONAHA.120.14759
   PubMed Web of Science ®Google Scholar
• Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–1968.7671380
   PubMed Web of Science ®Google Scholar
• Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4(3 Suppl):S61–4. doi:10.1016/j.hrthm.2006.12.00617336887
   PubMed Web of Science ®Google Scholar
• Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114(9):1500–1515. doi:10.1161/CIRCRESAHA.114.30377224763467
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li S, Sheng X, et al. Interactions between metabolism regulator adiponectin and intrinsic cardiac autonomic nervous system: a potential treatment target for atrial fibrillation. Int J Cardiol. 2020;302:59–66. doi:10.1016/j.ijcard.2019.12.03131889562
   PubMed Web of Science ®Google Scholar
• Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137–154. doi:10.1038/s41569-018-0108-730410105
   PubMed Web of Science ®Google Scholar
• Organ CL, Otsuka H, Bhushan S, et al. Choline diet and its gut microbe-derived metabolite, Trimethylamine N-Oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016;9(1):e002314. doi:10.1161/CIRCHEARTFAILURE.115.00231426699388
   PubMed Web of Science ®Google Scholar
• Cheng WL, Li SJ, Lee TI, et al. Sugar fructose triggers gut dysbiosis and metabolic inflammation with cardiac arrhythmogenesis. Biomedicines. 2021;9(7):728. doi:10.3390/biomedicines907072834201938
   PubMed Web of Science ®Google Scholar
• Guazzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart (British Cardiac Society). 2009;95(2):102–106. doi:10.1136/hrt.2007.13527719109515
   PubMed Web of Science ®Google Scholar
• Cai H, Li Z, Goette A, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106(22):2854–2858. doi:10.1161/01.CIR.0000039327.11661.1612451014
   PubMed Web of Science ®Google Scholar
• Corban MT, Godo S, Burczak DR, et al. Coronary endothelial dysfunction is associated with increased risk of incident atrial fibrillation. J Am Heart Assoc. 2020;9(8):e014850. doi:10.1161/JAHA.119.01485032295466
   PubMed Web of Science ®Google Scholar
• Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol. 2007;99(9):1258–1262. doi:10.1016/j.amjcard.2006.12.04417478154
   PubMed Web of Science ®Google Scholar
• Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension (Dallas, Tex: 1979). 2009;54(1):3–10. doi:10.1161/HYPERTENSIONAHA.109.129114
   Web of Science ®Google Scholar
• Ungvari Z, Tarantini S, Sorond F, Merkely B, Csiszar A. Mechanisms of vascular aging, A geroscience perspective: JACC focus seminar. J Am Coll Cardiol. 2020;75(8):931–941. doi:10.1016/j.jacc.2019.11.06132130929
   PubMed Web of Science ®Google Scholar
• Wang B, Xu Y, Hou X, et al. Small intestinal bacterial overgrowth in subclinical hypothyroidism of pregnant women. Front Endocrinol (Lausanne). 2021;12:604070. doi:10.3389/fendo.2021.60407034108932
   PubMed Web of Science ®Google Scholar
• Sittipo P, Lobionda S, Lee YK, Maynard CL. Intestinal microbiota and the immune system in metabolic diseases. J Microbiol. 2018;56(3):154–162. doi:10.1007/s12275-018-7548-y29492872
   PubMed Web of Science ®Google Scholar
• Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017;15(10):630–638. doi:10.1038/nrmicro.2017.5828626231
   PubMed Web of Science ®Google Scholar
• Tang WH, Hazen SL. The gut microbiome and its role in cardiovascular diseases. Circulation. 2017;135(11):1008–1010. doi:10.1161/CIRCULATIONAHA.116.02425128289004
   PubMed Web of Science ®Google Scholar
• Bibbò S, Ianiro G, Giorgio V, et al. The role of diet on gut microbiota composition. Eur Rev Med Pharmacol Sci. 2016;20(22):4742–4749.27906427
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk AA, Zheng D, Elinav E. Diet-microbiota interactions and personalized nutrition. Nat Rev Microbiol. 2019;17(12):742–753. doi:10.1038/s41579-019-0256-831541197
   PubMed Web of Science ®Google Scholar
• Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. J Nutr. 2003;133(5):1302–1307. doi:10.1093/jn/133.5.130212730414
   PubMed Web of Science ®Google Scholar
• Zhang AQ, Mitchell SC, Smith RL. Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol. 1999;37(5):515–520. doi:10.1016/S0278-6915(99)00028-910456680
   PubMed Web of Science ®Google Scholar
• Aldana-Hernández P, Leonard KA, Zhao YY, Curtis JM, Field CJ, Jacobs RL. Dietary choline or trimethylamine N-oxide supplementation does not influence atherosclerosis development in Ldlr-/- and Apoe-/- male mice. J Nutr. 2020;150(2):249–255. doi:10.1093/jn/nxz21431529091
   PubMed Web of Science ®Google Scholar
• Lin T, Li K, He W, Chen L, Wang T, Wang N. Trimethylamine N-oxide: a new therapeutic target for atrial fibrillation? Int J Cardiol. 2019;274:194. doi:10.1016/j.ijcard.2018.07.14730449329
   PubMed Web of Science ®Google Scholar
• Cho CE, Taesuwan S, Malysheva OV, et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol Nutr Food Res. 2017;61(1):1600324.
   Web of Science ®Google Scholar
• Wang Z, Roberts AB, Buffa JA, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163(7):1585–1595. doi:10.1016/j.cell.2015.11.05526687352
   PubMed Web of Science ®Google Scholar
• Xu J, Yang Y. Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases. Gut Microbes. 2021;13(1):1936379. doi:10.1080/19490976.2021.193637934170211
   PubMed Web of Science ®Google Scholar